Tom Price, will sell off stock holdings to avoid potential conflicts of interest ... Cigna Corp. will not cover Mylan's EpiPen epinephrine auto-injector in 2017. Instead, the insurer will cover Mylan's $300 generic version of the …
HHS Secretary
This is a proprietary stock volatility rating created by Capital Market Laboratories (CMLviz) based on a large number of data interactions for Mylan N.V. (NASDAQ:MYL) . We also look at broad measures of the S&P 500 …
Volatility
Mylan N.V. (NASDAQ: MYL) has been all over the news recently... And the news isn’t good. In case you’re unaware, the company has raised the price of its lifesaving EpiPen - the only drug of its kind with FDA …
Stock
Mylan's (MYL) own generic version of the EpiPen should outperform Kaleo's Auvi-Q, due out in 2017, Mizuho's Irina Koffler said. The biggest annual event for biotech and pharma investors starts Monday with the kickoff of …
Mylan has had a rough time in the market as of late, and for good reason. The company's product, Epipen has taken center stage among news outlets thanks to recent price hikes, and that's concerning investors. As a …
The Dip
Mylan could be facing another issue when it comes to the EpiPen, a drug used to treat severe allergic reactions that has seen a price increase of more than 500% since 2007. The company's stock was down by more than …
Overcharging
Mylan's stock is down over 30% in 2016, making it more attractively valued than it's been in a long time. While all of the attention this year has been about EpiPen, the reality is that the product will probably account for only …
The Motley Fool
In an 8-K filing, generic drug maker Mylan N.V. (MYL - Free Report) revealed restructuring programs in certain locations in an attempt to streamline its operations globally as it focuses on the integration of acquired …
ZACKS1mon
LSV Asset Management cut its position in Mylan Inc. (NASDAQ:MYL) by 7.3% during the third quarter, Holdings Channel reports. The firm owned 665,844 shares of the company’s stock after selling 52,605 shares during the …
Stake